The full article, entitled "The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine", can be accessed via this link.
Two years after the completion of the European Commission funded, EVI co-ordinated TRANSVAC project, results are still emerging, such as the recent article in PLOS neglected tropical diseases: Deep Sequencing Analysis of the Ixodes ricinus Haemocytome
Commissioned research for European Small and Medium size Enterprises (SME) and Public Health Organizations.
The ADITEC project is looking to support SMEs and public health organizations from within or outside the ADITEC consortium in vaccine development work that will result in public health benefit. We are actively seeking research proposals clearly aimed at vaccine development, where specific support can be requested in the areas listed below. These services are offered by current ADITEC consortium partners and are available free of charge to the requesting SME or public health organization, upon approval of the proposal.
Deadline: 30 October 2015 5:00 p.m. CET
Muhammed Afolabi (MRC Gambia) received an ASTMH 2015 Annual Meeting Travel Award that is supported in part by the Bill & Melinda Gates Foundation.
The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance is delighted to announce to you its maiden Vaccine Pharmacovigilance Fellowship Programme. Deadline for registration is 21st August 2015. For enquiries kindly contact us at training [at] who-pvafrica [dot] org
EVI congratulates GlaxoSmithKline and PATH Malaria Vaccine Initiative (MVI) on their resounding success on the development of MosquirixTM, also known as RTS,S, for use in children aged six weeks to 17 months.
The Institute of Tropical Medicine and International Health in Berlin is offering a two week Advanced Vaccinology Course at Campus Virchow Klinikum CVK Charité, Berlin, 11-22 January 2016.
Acess flyer for more information and application form
BELLEROPHON would like to make a call for the process development and production in E. coli according to Good Manufacturing Practice (GMP) of a protein vaccine candidate to be used in toxicological and phase I studies. The subcontracting is expected in Q4 2015.
- 1 of 11